Obsessive-Compulsive Disorder Study for Children and Adolescents

If your child or teen (ages 7-17) is suffering from obsessive-compulsive disorder (OCD) he or she may be able to participate in a research study at the National Institute of Mental Health (NIMH). We are investigating the medication riluzole.


Children and adolescents with a primary diagnosis of OCD, or both autism spectrum disorder and OCD may be eligible. Participants will be randomized to either riluzole or placebo (pill with no active ingredient) for 12 weeks. At the end of 12 weeks, all participants will have the option of taking riluzole (no chance of placebo). A comprehensive psychiatric and medical evaluation and follow-up visits approximately monthly for 6 months, and at 9 and 12 months, are included. There is no cost to participate; travel assistance may be provided.

Organization: 
National Institute of Mental Health
Principal Investigator: 
Paul Grant, MD
Contact: 
Lorraine Lougee, LCSW-C, 301-435-6652, 301-496-5323, or OCDNIMH@intra.nimh.nih.gov
Location: 
Bethesda, MD
State: 
Maryland

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Privacy Policy 
© ADAA, 2010-2014